- Home
- NTCL vs SLRN Comparison
NTCL vs SLRN Comparison
Compare NTCL & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCL
- SLRN
- Stock Information
- Founded
- NTCL 2003
- SLRN 2020
- Country
- NTCL China
- SLRN United States
- Employees
- NTCL N/A
- SLRN N/A
- Industry
- NTCL
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- NTCL
- SLRN Health Care
- Exchange
- NTCL NYSE
- SLRN Nasdaq
- Market Cap
- NTCL 193.8M
- SLRN 224.6M
- IPO Year
- NTCL 2024
- SLRN 2023
- Fundamental
- Price
- NTCL $28.30
- SLRN $2.36
- Analyst Decision
- NTCL
- SLRN Hold
- Analyst Count
- NTCL 0
- SLRN 5
- Target Price
- NTCL N/A
- SLRN $9.60
- AVG Volume (30 Days)
- NTCL 765.5K
- SLRN 703.6K
- Earning Date
- NTCL 01-01-0001
- SLRN 05-16-2025
- Dividend Yield
- NTCL N/A
- SLRN N/A
- EPS Growth
- NTCL N/A
- SLRN N/A
- EPS
- NTCL N/A
- SLRN N/A
- Revenue
- NTCL $10,101,647.00
- SLRN N/A
- Revenue This Year
- NTCL N/A
- SLRN $267.11
- Revenue Next Year
- NTCL N/A
- SLRN N/A
- P/E Ratio
- NTCL N/A
- SLRN N/A
- Revenue Growth
- NTCL N/A
- SLRN N/A
- 52 Week Low
- NTCL $4.59
- SLRN $1.85
- 52 Week High
- NTCL $51.80
- SLRN $7.25
- Technical
- Relative Strength Index (RSI)
- NTCL N/A
- SLRN 47.93
- Support Level
- NTCL N/A
- SLRN $2.34
- Resistance Level
- NTCL N/A
- SLRN $2.64
- Average True Range (ATR)
- NTCL 0.00
- SLRN 0.17
- MACD
- NTCL 0.00
- SLRN 0.02
- Stochastic Oscillator
- NTCL 0.00
- SLRN 48.70
About NTCL NETCLASS TECHNOLOGY INC
Netclass Technology Inc is a business-to-business smart education specialist, providing IT solutions to schools, training institutions, corporations, public agencies and other institutions or corporate customers. It offers SaaS subscription service and application development. The solution's modules include teaching management, campus management, online teaching, online examination, epidemic prevention and control, education credit blockchain system, and lecturer evaluation services.
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines.